Carnostatine hydrochloride SAN9812 hydrochloride|西域试剂

Carnostatine hydrochloride SAN9812 hydrochloride,99.90%

产品编号：Bellancom-112431A| 分子式：C₁₀H₁₇ClN₄O₄| 分子量：292.72

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-112431A	￥1200.00	杭州北京（现货）
Bellancom-112431A	￥3500.00	杭州北京（现货）
Bellancom-112431A	￥6000.00	杭州北京（现货）
Bellancom-112431A	￥10000.00	杭州北京（现货）
Bellancom-112431A	￥15000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Carnostatine hydrochloride SAN9812 hydrochloride

产品介绍

Carnostatine hydrochloride (SAN9812 hydrochloride) 是一种有效的选择性肌肽酶 1 (CN1) 抑制剂，对人重组 CN1 的 K_i 值为 11 nM。Carnostatine hydrochloride 有潜力用于糖尿病性肾病 (DN) 的研究。

生物活性

Carnostatine hydrochloride (SAN9812 hydrochloride) is a potent and selective carnosinase 1 (CN1) inhibitor with a K_i of 11 nM for human recombinant CN1. Carnostatine hydrochloride can be used for the treatment of diabetic nephropathy (DN).

体外研究

Carnostatine (SAN9812) also inhibits CN1 activity in human serum and serum of transgenic mice-overexpressing human CN1. Carnostatine, with an IC₅₀ value of 18 nM on human recombinant CN1 at a carnosine concentration of 200 µM, i.e., close to the K_m of 190 µM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Subcutaneous administration of 30 mg/kg Carnostatine (SAN9812) leads to a sustained reduction in circulating CN1 activity in human CN1 transgenic (TG) mice. Simultaneous administration of Carnosine and Carnostatine increases carnosine levels in plasma and kidney by up to 100-fold compared to treatment-naïve CN1-overexpressing mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Human carnosinase (CNDP1) transgenic mice on a BTBR wt/ob background
Dosage:	3 mg/kg i.v. or 30 mg/kg s.c. (Pharmacokinetic Analysis)
Administration:	Single bolus administration
Result:	Subcutaneous administration of 30 mg/kg led to a sustained reduction in circulating CN1 activity.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Human carnosinase (CNDP1) transgenic mice on a BTBR wt/ob background
Dosage:	3 mg/kg i.v. or 30 mg/kg s.c. (Pharmacokinetic Analysis)
Administration:	Single bolus administration
Result:	Subcutaneous administration of 30 mg/kg led to a sustained reduction in circulating CN1 activity.

性状

Oil

溶解性数据

In Vitro:

H₂O : ≥ 250 mg/mL (854.06 mM)

DMSO : 250 mg/mL (854.06 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4162 mL	17.0812 mL	34.1623 mL
5 mM	0.6832 mL	3.4162 mL	6.8325 mL
10 mM	0.3416 mL	1.7081 mL	3.4162 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶